The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).

Summit Therapeutics' recent stock sell-off reflects regulatory uncertainty rather than drug failure. Click here to read an ...

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Dana-Farber Cancer Institute investigators launch a first-of-its kind study to use a novel blood test to identify people who ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Lung cancer is the leading cause of cancer death in Western Australia, and is also the most common and one of the least ...